Financial Performance Highlights
SPARC reported a dramatic turnaround with FY26 consolidated net profit of ₹15,532 crores versus a FY25 loss of ₹342.5 crores. Revenue from operations surged to ₹18,791.68 crores from ₹416.34 crores in FY25. This exceptional performance was primarily driven by recognition of ₹18,400 crores income from the sale of a Priority Review Voucher (PRV) granted by the US FDA for Sezaby®, which was sold for USD 195 million on April 30, 2026.
Key Event - Priority Review Voucher
The company was granted a Priority Review Voucher by the US FDA on February 03, 2026, for Sezaby® (benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for neonatal seizures). The PRV income has been recognized as a government grant under Ind AS 20 and represents the primary reason for the financial turnaround.
R&D Pipeline Progress
1. Sezaby for Neonatal Seizures
FDA-approved formulation with efforts ongoing to remove unapproved DESI phenobarbital formulations from market.
2. SPARC-121 for Alopecia Areata
Novel topical agent completed Phase 1a SAD study, with Phase 1b MAD study actively recruiting and interim readout expected in Q3 FY2026-27. Also exploring application in Vitiligo.
3. SPARC-122 for Cancer
Anti-MUC1 ADC received IND approvals from US, Australia, and India regulators. Phase 1a dose escalation study in solid tumors actively enrolling at 11 sites across three geographies.
4. PDP-716 for Glaucoma
Once-daily formulation of Brimonidine licensed to Visiox Pharma (now Ocuvex Therapeutics), facing regulatory challenges with API manufacturing facility issues.
Corporate Actions and Financing
SPARC completed a preferential issue of 3.85 crore warrants to promoter group entity Shanghvi Finance Private Limited at ₹155.80 per warrant, raising ₹600 crores. The Board and shareholders also approved the SPARC Employees Stock Option Scheme 2026, though no options were granted as of the report date.
Balance Sheet and Risk Factors
Total assets increased to ₹21,708.76 crores from ₹3,355.34 crores in FY25, while borrowings increased to ₹5,593.15 crores from ₹2,689.34 crores. Key risks identified include foreign exchange risk (5% INR movement impacts profit by ₹608 lakhs), interest rate risk, and tax litigations totaling ₹8,474 crores.
Governance and Compliance
The Company received a qualified Secretarial Audit Report noting an inadvertent lapse in complying with SEBI LODR regarding director appointments, resulting in fines from NSE and BSE. Significant board changes occurred during FY26 with several independent director retirements and new appointments.
AGM Details and Voting
The 21st Annual General Meeting is scheduled for August 10, 2026 via video conference, with remote e-voting from August 6-9, 2026. Key resolutions include adoption of financial statements and appointment of Mr. Anil Kumar Raghavan as Managing Director & CEO.
Audit Matters
Auditors identified three key audit matters: revenue recognition from complex R&D contractual arrangements, recognition of PRV income as a government grant under Ind AS 20, and evaluation of direct and indirect tax litigations totaling ₹8,473.94 crores. The auditors issued an unmodified opinion on both standalone and consolidated financial statements.